CTLA4 and primary progressive multiple sclerosis: Nevertheless, our finding of a more significant increase in the percentage of Treg CTLA-4+ cells in ocrelizumab treated PPMS subjects compared to untreated PPMS subjects corresponds to a slight EDSS decrease (6%) in ocrelizumab treated PPMS subjects.